Intravenous Immunoglobulin in Patients With Anti-GAD Antibody-Associated Neurological Diseases and Patients With Inflammatory Myopathies: Effects on Clinicopathological Features and Immunoregulatory Genes

2005 ◽  
Vol 29 (3) ◽  
pp. 255-270 ◽  
Author(s):  
Marinos C. Dalakas
2014 ◽  
Vol 72 (12) ◽  
pp. 966-971
Author(s):  
Paulo Victor Sgobbi de Souza ◽  
Wladimir Bocca Vieira de Rezende Pinto ◽  
Acary Souza Bulle Oliveira

During recent years, an increasing number of neuromuscular diseases have been recognized either to be caused primarily by autoimmune mechanisms, or to have important autoimmune components. The involved pathophysiological mechanisms and clinical manifestations have been better recognized and many of these disorders are potentially treatable by immunosuppression or by immunomodulation with intravenous immunoglobulin (IVIg). IVIg has been tried in a variety of immune-mediated neurological diseases, being target of widespread use in central and peripheral nervous systems diseases. Objective To give an overview of the main topics regarding the mechanism of action and different therapeutic uses of IVIg in neurological practice, mainly in neuromuscular diseases.


2008 ◽  
Vol 15 (9) ◽  
pp. 893-908 ◽  
Author(s):  
I. Elovaara ◽  
S. Apostolski ◽  
P. van Doorn ◽  
N. E. Gilhus ◽  
A. Hietaharju ◽  
...  

2019 ◽  
Vol 140 (4) ◽  
pp. 290-295 ◽  
Author(s):  
Jonas Graf ◽  
Jens Ingwersen ◽  
Klaudia Lepka ◽  
Philipp Albrecht ◽  
Hans‐Peter Hartung ◽  
...  

2015 ◽  
Vol 13 (1) ◽  
pp. 34-46 ◽  
Author(s):  
Jan D. Lünemann ◽  
Isaak Quast ◽  
Marinos C. Dalakas

1996 ◽  
Vol 60 (4) ◽  
pp. 359-361 ◽  
Author(s):  
A Otten ◽  
M Vermeulen ◽  
P M Bossuyt ◽  
A Otten

Sign in / Sign up

Export Citation Format

Share Document